Physician profile
Bob Ly
NPI 1659781516
$684.87
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $21.17 · 2021: $66.11 · 2022: $116 · 2023: $143 · 2024: $13.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $108.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $93.02 | 2019 | |
| Tandem Diabetes Care, INC. | $92.97 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $56.29 | 2022-2023 | Minimed 780g |
| Novo Nordisk INC | $45.87 | 2020-2021 | |
| Insulet Corporation | $41.41 | 2021 | |
| Dexcom, INC. | $39.43 | 2022-2023 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $29.43 | 2023-2024 | Ilet Bionic Pancreas |
| Becton, Dickinson and Company | $29.01 | 2019 | |
| Pfizer INC. | $27.89 | 2023 | |
| Alexion Pharmaceuticals, INC. | $26.19 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.17 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.99 | 2019 | |
| Cequr Corporation | $15.71 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.44 | 2019 | |
| Lilly USA, LLC | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bob Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.